Mouth mucous membranes lesions
![]() |
BUCCAGEL® : PROTECTIVE ORAL GEL for topical application.
The lubricating property of O.G.T. allows painless massage of the lesions to which a protective film adheres forming a “shield” against aggressions (food, contact with the denture, etc.). Presentation : tube of 5 ml en France. BUCCAGEL® is distributed in the European Community under the regulatory status of a Medical Device Class I complying with the requirements of Directive 93/42/EEC. BUCCAGEL® is distributed in France by TONIPHARM Laboratory. BUCCAGEL® is distributed all over Europe under different trade names. |
Xerostomia
![]() |
ÆQUASYAL® is a lubricating and protective mouth spray solution indicated for the treatment of xerostomia or dry mouth. ÆQUASYAL® oral spray reduces feeling of dry mouth and improves the associated symptoms: inflammation of the oral mucosa, difficulties of deglutition, mastication, etc. LPPR : 65% (reimbursement by French Social Security). Presentation : 40 ml bottle for 2 months of treatment. In Europe, ÆQUASYAL® is a Medical Device Class I, complying with the requirements of Directive 93/42/EEC. In the U.S.A., ÆQUASYAL® is an FDA approved Medical Device under the 510 (k) regulation. ÆQUASYAL® is distributed in France by Laboratoire EISAI. |
Prevention of pressure ulcer and treatment of pressure erythema
![]() |
ULCILENE® protective solution is indicated in the prevention of pressure ulcer and the treatment of pressure erythema (warning lesion). ULCILENE® is an O.G.T. solution enriched with vitamin A and Omega 3 essential fatty acids. ULCILENE® restores the hydro lipid protective film of the skin, limits transcutaneous water loss, facilitates restoration of normal blood microcirculation, thereby promoting cell turnover and preventing pressure ulcer. ULCILENE® must be applied locally by gentle massage (with finger tip weight) to risk zones. Massage is not painful. ULCILENE® is a Medical Device Class I, complying with the requirements of Directive 93/42/EEC. Presentation : 20 ml spray bottle. |
Male and female alopecia
![]() |
The M-44® and SILICIUM 44® ranges are composed of 2 products :
Once daily application of the lotion is sufficient. M-44® and SILICIUM 44® control hair loss in less than 8 weeks. Hair do not need to be washed after application. M-44® and SILICIUM 44® are marketed in France and in the world under the Cosmetic Legislation. Presentation :
Distributed in pharmacies and parapharmacies |
Musculo-skeletal pain and inflammation
![]() |
OXYFLEX® Arthritis, rheumatic pain, muscle pain, etc. OXYFLEX® is a massage cream containing 20% O.G.T.. It is indicated for the relief of musculo-skeletal pain and inflammation. OXYFLEX® is distributed in the U.S.A. by TRUSOLUTIONS Corporation under the Cosmetic Legislation. OXYFLEX® can be distributed in Europe as a Medical Device.
|
Painful and leavy legs
![]() |
VENOXYL®, leg care Prolonged exposure to heat (during summer, heating, etc.) and long standing are harmful to legs venous circulation, generating pain and severe discomfort. O.G.T. stimulates superficial blood flow, providing immediate relief of tired legs or “heavy” legs. Marketing license granted to Laboratoire EFFISCIENCE in France.
|
Other products ready to be launched
The following O.G.T. formulations, validated by significant clinical trials, are ready to be commercialized :
topical treatment
- sunburn, erythema,
- chilblains, cold feet, cold hands,
- premenstrual breast pain, mastodynia,
- superficial contusions, ecchymoses,
- external haemorrhoids,
Laboratoires CARILENE can formulate and register a medical device
for
each of these indications, which will allow immediate marketing in the EEC.

Mouth mucous lesions





